| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 33.25% | JP Morgan | $51.5 → $53 | Maintains | Overweight |
| 06/30/2023 | 31.99% | JP Morgan | $49.5 → $52.5 | Maintains | Overweight |
| 06/12/2023 | 18.16% | B of A Securities | $56 → $47 | Downgrades | Buy → Neutral |
| 03/09/2023 | 23.19% | Itau BBA | → $49 | Downgrades | Outperform → Market Perform |
| 03/06/2023 | 30.74% | Morgan Stanley | $34 → $52 | Upgrades | Equal-Weight → Overweight |
| 02/16/2023 | 13.14% | HSBC | $43 → $45 | Maintains | Buy |
| 02/01/2023 | 25.71% | Citigroup | → $50 | Reinstates | → Buy |
| 09/06/2022 | 30.74% | Goldman Sachs | $60 → $52 | Maintains | Buy |
| 08/26/2022 | 0.57% | B of A Securities | $53 → $40 | Downgrades | Buy → Neutral |
| 07/06/2022 | -1.95% | Morgan Stanley | $48 → $39 | Maintains | Equal-Weight |
| 03/11/2022 | 8.11% | Wolfe Research | $38 → $43 | Upgrades | Underperform → Peer Perform |
| 01/11/2022 | 13.14% | Wolfe Research | → $45 | Downgrades | Peer Perform → Underperform |
| 12/20/2021 | 53.36% | Scotiabank | $63 → $61 | Upgrades | Sector Perform → Sector Outperform |
| 11/17/2021 | 15.65% | Wolfe Research | → $46 | Initiates Coverage On | → Peer Perform |
| 10/18/2021 | 25.71% | Morgan Stanley | $60 → $50 | Downgrades | Overweight → Equal-Weight |
| 08/19/2021 | 75.99% | Itau BBA | → $70 | Upgrades | Market Perform → Outperform |
| 05/14/2021 | 10.62% | Scotiabank | → $44 | Downgrades | Outperform → Sector Perform |
| 01/21/2021 | -1.95% | Bradesco Corretora | → $39 | Upgrades | Neutral → Outperform |
| 01/11/2021 | 4.34% | Credit Suisse | → $41.5 | Upgrades | Neutral → Outperform |
| 11/06/2020 | -33.38% | JP Morgan | → $26.5 | Upgrades | Neutral → Overweight |
| 06/22/2020 | -53.49% | JP Morgan | → $18.5 | Downgrades | Overweight → Neutral |
| 05/14/2020 | -69.83% | UBS | $18 → $12 | Maintains | Sell |
| 03/16/2020 | -54.75% | Morgan Stanley | $23 → $18 | Upgrades | Equal-Weight → Overweight |
| 02/20/2020 | -37.15% | JP Morgan | $20 → $25 | Upgrades | Neutral → Overweight |
| 01/27/2020 | -54.75% | UBS | → $18 | Downgrades | Neutral → Sell |
| 01/22/2020 | — | Scotiabank | Upgrades | Sector Perform → Sector Outperform | |
| 08/13/2019 | — | Bradesco Corretora | Downgrades | Outperform → Neutral | |
| 05/31/2019 | -29.6% | UBS | $35 → $28 | Maintains | Neutral |
| 05/06/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 02/28/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral |
What is the target price for Ternium (TX)?
The latest price target for Ternium (NYSE: TX) was reported by JP Morgan on August 21, 2023. The analyst firm set a price target for $53.00 expecting TX to rise to within 12 months (a possible 33.25% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ternium (TX)?
The latest analyst rating for Ternium (NYSE: TX) was provided by JP Morgan, and Ternium maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Ternium (TX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ternium, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ternium was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
Is the Analyst Rating Ternium (TX) correct?
While ratings are subjective and will change, the latest Ternium (TX) rating was a maintained with a price target of $51.50 to $53.00. The current price Ternium (TX) is trading at is $39.78, which is out of the analyst's predicted range.